<DOC>
	<DOCNO>NCT01716156</DOCNO>
	<brief_summary>This study compare two different duration treatment grazoprevir ( MK-5172 ) combination ribavirin ( RBV ) treatment-na√Øve non-cirrhotic interferon-eligible interleukin 28b CC ( IL28B CC ) genotype participant genotype 1 ( GT1 ) -positive chronic hepatitis C ( CHC ) . Participants randomize receive 12 24 week combination therapy .</brief_summary>
	<brief_title>A Study Different Durations Treatment With Grazoprevir ( MK-5172 ) Combination With Ribavirin Participants With Chronic Hepatitis C ( MK-5172-039 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic , compensate HCV GT 1 hepatitis C IL28B CC genotype Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom advance liver disease , cirrhosis No evidence cirrhosis hepatocellular carcinoma biopsy noninvasive test ( FibroScan and/or FibroTest ) Agree use two acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation ( female subject childbearing potential male subject female sexual partner childbearing potential ) NonGT 1 HCV infection , include mixed GT infection ( nonGT 1 ) nontypeable genotype Previous treatment interferon , RBV , approve experimental direct act antiviral ( ) , investigational therapy HCV Human immunodeficiency virus ( HIV ) positive know coinfected hepatitis B virus Evidence hepatocellular carcinoma ( HCC ) evaluation HCC Currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study Diabetes and/or hypertension clinically significant ocular examination finding Current moderate severe depression history depression associate hospitalization , electroconvulsive therapy , severe disruption daily function , suicidal homicidal ideation and/or attempt , history severe psychiatric disorder Clinical diagnosis substance abuse Current history seizure disorder , stroke , transient ischemic attack Immunologicallymediated disease Chronic pulmonary disease Clinically significant cardiac abnormalities/dysfunction Active clinical gout within last year Hemoglobinopathy myelodysplastic syndrome History organ transplant Poor venous access Indwelling venous catheter History gastric surgery malabsorption disorder Severe concurrent disease Evidence active suspect malignancy , evaluation malignancy , history malignancy , within last 5 year Pregnant , lactating , expect conceive donate egg Male participant whose female partner pregnant Member family member investigational study staff sponsor staff directly involve study History chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>